LitAlert ~~ GeneLit.com

    • Germline genetics of prostate cancer.
    • Khan HM, Cheng HH.
    • Prostate. 2022 Aug;82 Suppl 1:S3-S12. doi: 10.1002/pros.24340.
    • Clinical implications of homologous recombination repair mutations in prostate cancer.
    • Cresta Morgado P, Mateo J.
    • Prostate. 2022 Aug;82 Suppl 1:S45-S59. doi: 10.1002/pros.24352.
    • Risk Reducing Bilateral Salpingo-Oopherectomy for BRCA Mutation Carriers via Transvaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) Approach.
    • Goldenberg M, Revivo PE, Gurevitch S, Mashiach R, Mohr-Sasson A.
    • Int J Gynaecol Obstet. 2022 Jun 3. doi: 10.1002/ijgo.14294. Epub ahead of print.
    • Population-based BRCA1/2 testing programmes are highly acceptable in the Jewish community: results of the JeneScreen Study.
    • Tiller JM, Cousens NE, Kaur R, Rowley S, Ko YA, Mahale S, Bankier A, Meiser B, Barlow-Stewart K, Burnett L, Jacobs C, James P, Trainer A, Neil S, Campbell IG, Andrews L, Delatycki M.
    • J Med Genet. 2022 Jun 3:jmedgenet-2022-108519. doi: 10.1136/jmedgenet-2022-108519. Epub ahead of print.
    • Breast cancer risk in women from Ghana carrying rare germline pathogenic mutations.
    • Ahearn TU, Pal Choudhury P, Derkach A, Wiafe-Addai B, Awuah B, Yarney J, Edusei L, Titiloye N, Adjei E, Vanderpuye V, Aitpillah F, Dedey F, Oppong J, Osei-Bonsu EB, Duggan MA, Brinton LA, Allen J, Luccarini C, Baynes C, Carvalho S, Dunning AM, Davis Lynn BC, Chanock SJ, Hicks BD, Yeager M, Chatterjee N, Biritwum R, Clegg-Lamptey JN, Nyarko K, Wiafe S, Ansong D, Easton DF, Figueroa JD, Garcia-Closas M.
    • Cancer Epidemiol Biomarkers Prev. 2022 Jun 2:cebp.EPI-21-1397-E.2021-12-9 11:31:59.213. doi: 10.1158/1055-9965.EPI-21-1397. Epub ahead of print.
    • Association between ancestry-specific 6q25 variants and breast cancer subtypes in Peruvian women.
    • Zavala VA, Casavilca-Zambrano S, Navarro Vásquez J, Castañeda CA, Valencia G, Morante Z, Calderón M, Abugattas JE, Gomez H, Fuentes HA, Liendo-Picoaga R, Cotrina JM, Monge C, Neciosup SP, Huntsman S, Hu D, Sanchez SE, Williams MA, Nunez-Marrero A, Godoy L, Hechmer A, Olshen AB, Dutil J, Ziv E, Zabaleta J, Gelaye B, Vasquez J, Galvez-Nino M, Enriquez-Vera D, Vidaurre T, Fejerman L.
    • Cancer Epidemiol Biomarkers Prev. 2022 Jun 2:cebp.EPI-22-0069-A.2022-1-20 15:23:11.350. doi: 10.1158/1055-9965.EPI-22-0069. Epub ahead of print.
    • BRCA variants do not increase the risk of adverse reactions in patients with ovarian cancer: A single-center real-world study.
    • LI K, Zeng J, Zhang M, Yin R, Li Z.
    • Front Oncol. 2022 Jun 2;12:807748. doi: 10.3389/fonc.2022.807748.
    • DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries.
    • Abdi B, Basset N, Perrot E, Benderra MA, Khalil A, Oudard S, Blanchet P, Brureau L, Coulet F, Cussenot O, Cancel-Tassin G.
    • Prostate. 2022 Jun 2. doi: 10.1002/pros.24374. Epub ahead of print.
    • The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
    • Liu AJ, Kosiorek HE, Ueberroth BE, Jaeger E, Ledet E, Kendi AT, Tzou K, Quevedo F, Choo R, Moore CN, Ho TH, Singh P, Keole SR, Wong WW, Sartor O, Bryce AH.
    • Prostate. 2022 Jun 2. doi: 10.1002/pros.24375. Epub ahead of print.
    • Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series.
    • Zhao L, Singh V, Ricca A, Lee P.
    • J Med Cases. 2022 May;13(5):240-243. doi: 10.14740/jmc3918. Epub 2022 May 7.